Non-invasive Brain Stimulation System Market Key Highlights:
Market Size (2024): USD 1,465 Million
Projected Market Size (2034): USD 2,802 Million
CAGR (2024-2034): 6.7%
Pricing Analysis:
Price Growth
Regional Variations
Market Historic Sales
Total sales volume, year-over-year growth, product categories, and market share.
Revenue Estimation
Forecasting future revenues based on historical data, market trends, and economic indicators.
Sales by Region
Breakdown of sales performance across different geographical areas.
Revenue by Manufacturer
Analysis of revenue contributions from different manufacturers in the market.
Non-invasive Brain Stimulation System Market Definition
Neurological conditions are increasingly becoming more prevalent globally. Noninvasive Brain Stimulation (NIBS) is used for the diagnosis and adjunct treatment of brain diseases. Noninvasive brain stimulation (NIBS) is safe, painless, and has minimal side effects. This technique is widely adopted by thousands of people around the world to alleviate the effects of issues related to speaking, swallowing, movement, and various other related functions. Transcranial magnetic stimulation (TMS) and transcranial electrical stimulation (tES) are the most popular advanced techniques used to alter brain functions for therapeutic and investigative purposes. NIBS is gaining significant traction among clinicians and researchers due to its promising potential as a neurophysiologic diagnostic tool that can provide non-pharmacological and noninvasive neuromodulatory treatments for various mental diseases.
The rising prevalence of numerous neurological conditions, such as Parkinson’s disease, Alzheimer's disease, migraine, and other neuro-related disorders has led to an increasing demand for non-invasive brain stimulation systems. Geriatric people are more susceptible to neurological illnesses. The surge in the aging population is anticipated to drive up the market expansion in the coming years.
The increase in drug approvals by the U.S. Food and Drug Administration (FDA) is projected to lucrative growth opportunities to the market. For instance, In July 2023, Boston Scientific Corporation announced it had received U.S. Food and Drug Administration (FDA) approval for the Vercise Neural Navigator 5 Software, which when used as part of the Vercise Genus Deep Brain Stimulation (DBS) Systems, can provide clinicians with simple and actionable data for efficient programming in the treatment of people living with Parkinson’s disease or essential tremor.
Download
Order Databook
Actionable Solutions
